
Seven-Year Safety Review Confirms Brodalumab’s Steady Risk Profile in US Postmarketing Surveillance
At the 2025 Society of Dermatology Physician Associates (SDPA) Summer Dermatology Conference, a poster presented by Lebwohl et al offered a comprehensive update on the long-term safety of brodalumab (Siliq; Bausch Health Companies Inc).1 Now in its seventh …